Canada Pension Plan Investment Board Buys 42,700 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

Canada Pension Plan Investment Board boosted its position in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 27.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 200,200 shares of the company's stock after purchasing an additional 42,700 shares during the period. Canada Pension Plan Investment Board owned about 0.17% of 10x Genomics worth $2,875,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Atria Wealth Solutions Inc. grew its holdings in shares of 10x Genomics by 9.6% during the fourth quarter. Atria Wealth Solutions Inc. now owns 10,788 shares of the company's stock worth $155,000 after buying an additional 943 shares in the last quarter. Blue Trust Inc. grew its stake in shares of 10x Genomics by 73.1% during the 4th quarter. Blue Trust Inc. now owns 3,075 shares of the company's stock worth $44,000 after acquiring an additional 1,299 shares in the last quarter. Sound Income Strategies LLC grew its stake in shares of 10x Genomics by 65.2% during the 4th quarter. Sound Income Strategies LLC now owns 3,370 shares of the company's stock worth $48,000 after acquiring an additional 1,330 shares in the last quarter. Signaturefd LLC raised its holdings in shares of 10x Genomics by 424.6% in the fourth quarter. Signaturefd LLC now owns 1,794 shares of the company's stock valued at $26,000 after purchasing an additional 1,452 shares during the last quarter. Finally, KBC Group NV lifted its position in shares of 10x Genomics by 57.3% in the fourth quarter. KBC Group NV now owns 5,072 shares of the company's stock worth $73,000 after purchasing an additional 1,847 shares in the last quarter. Institutional investors and hedge funds own 84.68% of the company's stock.

Analysts Set New Price Targets

Several brokerages have issued reports on TXG. Citigroup lowered their price target on shares of 10x Genomics from $20.00 to $15.00 and set a "buy" rating on the stock in a research note on Tuesday, March 4th. Canaccord Genuity Group dropped their target price on 10x Genomics from $20.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday, February 13th. Morgan Stanley decreased their price target on 10x Genomics from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. Weiss Ratings reiterated a "sell (e+)" rating on shares of 10x Genomics in a research note on Tuesday, April 8th. Finally, Stifel Nicolaus lowered their target price on shares of 10x Genomics from $21.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday, February 13th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $19.79.

10x Genomics Stock Up 3.6 %

Shares of TXG stock opened at $7.96 on Wednesday. 10x Genomics, Inc. has a 12-month low of $6.78 and a 12-month high of $29.37. The firm has a 50 day moving average price of $9.71 and a two-hundred day moving average price of $13.31. The company has a market capitalization of $973.52 million, a PE ratio of -5.24 and a beta of 2.01.

10x Genomics (NASDAQ:TXG - Get Free Report) last released its quarterly earnings results on Wednesday, February 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. As a group, research analysts expect that 10x Genomics, Inc. will post -1.43 EPS for the current year.

Insider Activity at 10x Genomics

In related news, Director Alan Mateo bought 40,000 shares of the business's stock in a transaction dated Friday, February 21st. The stock was purchased at an average cost of $11.14 per share, for a total transaction of $445,600.00. Following the transaction, the director now owns 61,691 shares in the company, valued at $687,237.74. The trade was a 184.41 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Benjamin J. Hindson sold 4,573 shares of the firm's stock in a transaction on Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $50,623.11. Following the completion of the transaction, the insider now owns 335,324 shares in the company, valued at $3,712,036.68. The trade was a 1.35 % decrease in their position. The disclosure for this sale can be found here. 10.03% of the stock is currently owned by corporate insiders.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.

Want to see what other hedge funds are holding TXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics, Inc. (NASDAQ:TXG - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.